Biogen Idec Inc. (NASDAQ: BIIB) recently presented new clinical data at the ISTH Congress in Amsterdam supporting its hemophilia A candidate, ELOCTATE, and its hemophilia B candidate, ALPROLIX. Both products are being developed with Swedish Orphan Biovitrum AB using Biogen's proprietary Fc fusion technology designed...
Biogen (Nasdaq: BIIB) has entered a definitive agreement to acquire private biotech firm RayThera Inc. for up to $1 billion in total potential value. The deal structure includes an upfront payment combined with clinical and regulatory milestone payments, contingent on the achievement of future development...
Biogen Inc. reported better-than-expected first-quarter sales and profits, indicating that progress on its Alzheimer's therapies and cost-reduction strategies are helping to counteract pressures within its multiple sclerosis (MS) franchise. Revenue increased 2 percent to $2.5 billion, while adjusted earnings climbed 18 percent to $3.57 per...
Biogen's stock, trading under the ticker BIIB on NASDAQ, experienced significant volatility following a strong performance at the beginning of February 2026 where it reached highs near $202. By early April 2026, however, the shares had declined to approximately $172. While the company boasts a...
Biogen Inc. shares closed at USD 227.60 on September 25, 2026, marking a 0.55 percent gain as the company reported robust second-quarter financial results. The biotechnology firm posted Q2 revenue of USD 2.74 billion, representing a 3.40 percent year-over-year increase that significantly exceeded analyst expectations...
